Bone Marrow Transplant in Treating Patients With Hematologic Cancers

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentCompleted15 to 55NCI, OtherMCC-11281
MCC-IRB-4188, NCI-G00-1759, NCT00005797

Trial Description


RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with hematologic cancers.

Further Study Information


  • Determine the progression free survival (PFS) and overall survival (OS) of patients with low risk myeloid disorders or older allogeneic recipients who are treated with high dose busulfan and cyclophosphamide and allogeneic bone marrow transplantation (BMT).
  • Determine the PFS and OS in patients with lymphoid and high risk myeloid disorders who are treated with etoposide, total body irradiation, and allogeneic BMT.
  • Evaluate the toxicities of these 2 regimens when combined with cyclosporine and methotrexate as graft versus host disease prophylaxis in these patients.
  • Evaluate the PFS and OS of allogeneic BMT in patients with multiple myeloma and chronic lymphocytic leukemia.


  • Regimen A: Patients with chronic myelogenous leukemia (CP1, AP/CP2) and other myeloproliferative disorders, myelodysplastic disorders, acute myelogenous leukemia (CR1), or multiple myeloma (not eligible to receive total body irradiation due to prior radiation) are treated with high dose busulfan and cyclophosphamide followed by allogeneic bone marrow transplantation (BMT). Patients receive oral busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 1 hour on days -3 and -2. Allogeneic bone marrow is infused on day 0.
  • Regimen B: Patients with acute myelogenous leukemia (at least CR2, relapsed), acute lymphoid leukemia (ALL), any acute leukemia with CNS involvement, multiple myeloma, or chronic lymphocytic leukemia are treated with total body irradiation and etoposide followed by allogeneic BMT. Patients receive total body irradiation (TBI) on days -7 to -4 for a total of 11 fractions and etoposide IV over 4 hours on day -3. Male patients with ALL receive a testicular boost in 2 fractions on 2 successive days during TBI. Allogeneic bone marrow is infused on day 0.

Patients in both regimens receive cyclosporine and methotrexate as graft versus host disease prophylaxis.

Patients are followed weekly for 3 months and then monthly for 1 year.

PROJECTED ACCRUAL: At least 50 patients with low risk myeloid disease, 50 patients with lymphoid malignancies, and 60 patients with high risk myeloid disease will be accrued for this study.

Eligibility Criteria


  • Histologically confirmed diagnosis of:
  • Acute myelogenous leukemia
  • Complete remission (CR) 1 - ALL except good cytogenetics defined as [(inv16, t(8,21), t(15,17)]
  • CR2
  • Induction failures
  • Relapsed OR
  • Acute lymphocytic leukemia (ALL)
  • CR1 - high risk defined as overt CNS involvement, 1 or more risk factors (age 30 and over, WBC at least 20,000/mm^3, at least 4 weeks to CR1, myeloid phenotype)
  • CR2
  • Induction failures
  • Relapsed OR
  • Chronic myelogenous leukemia
  • Chronic phase (CP) 1
  • Accelerated phase (AP)/CP2 OR
  • Chronic lymphocytic leukemia
  • At diagnosis - RAI stage III/IV or Binet C
  • Must undergo 1 induction regimen
  • Relapsed - any stage
  • Must have received no more than 3 regimens for diagnosis OR
  • Multiple myeloma
  • At diagnosis - stage II/III (primary refractory or sensitive)
  • Relapsed no more than 2 times - sensitive disease
  • Plasma cell leukemia OR
  • Myelodysplasia
  • All subtypes eligible OR
  • Myeloproliferative disorders
  • Poor response to medical therapy OR
  • Cytogenetic abnormalities
  • Must have a related donor who is genotypic 6 out of 6 HLA A, B, and DR match
  • Molecular DR matching required



  • 15 to 55

Performance status:

  • Karnofsky 80-100%

Life expectancy:

  • Not specified


  • See Disease Characteristics


  • Bilirubin no greater than 2.0 mg/dL
  • SGOT/SGPT no greater than 3 times upper limit of normal
  • PT/PTT normal


  • Creatinine no greater than 2.0 mg/dL
  • Creatinine clearance at least 60 mL/min


  • LVEF at least 45% by MUGA scan or echocardiography
  • No myocardial infarction within the past 6 months
  • No arrhythmias controlled by therapy


  • FEV_1 at least 50% predicted
  • DLCO at least 50% predicted


  • Not pregnant or nursing
  • Negative pregnancy test
  • No diabetes mellitus or thyroid disease that is not medically controlled
  • No psychosocial disorder that would preclude study compliance
  • No active serious infections
  • HIV negative
  • Donor must be HIV negative


Biologic therapy:

  • Not specified


  • See Disease Characteristics

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified

Trial Contact Information

Trial Lead Organizations/Sponsors

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

  • National Cancer Institute
Teresa Field, Study Chair

Link to the current record.
NLM Identifier NCT00005797 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to